Patterns of curative treatment for non-small cell lung cancer in New South Wales, Australia

被引:2
|
作者
Batumalai, Vikneswary [1 ,2 ]
Descallar, Joseph [1 ]
Gabriel, Gabriel [1 ]
Delaney, Geoff P. [1 ,3 ]
Oar, Andrew [4 ]
Barton, Michael B. [1 ,3 ]
Vinod, Shalini K. [1 ,3 ]
机构
[1] Univ New South Wales, Collaborat Canc Outcomes Res & Evaluat, Ingham Inst Appl Med Res, South Western Clin Sch, Sydney, NSW, Australia
[2] GenesisCare, Bldg 1&11,41-43 Bourke Rd, Alexandria, NSW 2015, Australia
[3] South Western Sydney Local Hlth Dist, Dept Radiat Oncol, Sydney, NSW, Australia
[4] Gold Coast Univ Hosp, Icon Canc Ctr, Gold Coast, Australia
关键词
curative; non-small cell lung cancer; practice patterns; radiotherapy; surgery; RADIOTHERAPY; CARE; COMORBIDITY; DISPARITIES; SURGERY; IMPACT; AGE;
D O I
10.1111/ajco.13811
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction There is a lack of large population-based studies examining patterns of curative treatment for non-small cell lung cancer (NSCLC) in Australia. This study aimed to evaluate the utilization of curative treatment for NCSLC at a population level and identify factors associated with its use in New South Wales (NSW), Australia. Methods Patients diagnosed with localized or locoregional NSCLC between 2009 and 2014 were identified from the NSW Central Cancer Registry. Curative treatment was defined as surgery or radiotherapy with a 45 Gy minimum dose. Univariate and multivariable analyses were performed to investigate factors associated with the receipt of curative treatment. A Cox proportional-hazards regression model was used to analyze the factors associated with 2-year overall survival (OS). Results Of the 5722 patients diagnosed with NSCLC in the study period, 3355 (59%) patients received curative treatment and 2367 (41%) patients did not receive curative treatment. The receipt of curative treatment was significantly associated with younger patients, female gender, localized disease, and Charlson Comorbidity Index (CCI) = 0. The use of curative treatment increased significantly over time from 2009 (55%) to 2014 (63%) and varied significantly from 24% to 70% between local health districts (LHDs) of residence. Younger age, female gender, localized disease, CCI = 0, and overseas country of birth were significantly associated with 2-year OS. The 2-year OS significantly improved from 70% in 2009 to 77% in 2014 for patients who received curative treatment. Conclusion The use of curative treatment for patients with potentially curable NSCLC was low at 59%. However, the use of curative treatment and survival have increased over time. Significant variation was noted in the use of curative treatment between LHDs.
引用
收藏
页码:E149 / E159
页数:11
相关论文
共 50 条
  • [21] Adjuvant and inductive systemic treatment in non-small cell lung cancer
    Wolf, M.
    CHIRURG, 2019, 90 (12): : 982 - 990
  • [22] Induction treatment before surgery for non-small cell lung cancer
    Eberhardt, WE
    Albain, KS
    Pass, H
    Putnam, JB
    Gregor, A
    Assamura, H
    Mornex, F
    Senan, S
    Belderbos, J
    Westeel, V
    Thomas, M
    Van Schil, P
    Vansteenkiste, J
    Manegold, C
    Mirimanoff, RO
    Stuschke, M
    Pignon, J
    Rocmans, P
    Shepherds, FA
    LUNG CANCER, 2003, 42 : S9 - S14
  • [23] Treatment of resectable stage IIIA non-small cell lung cancer
    Cardenal, Felipe
    Palmero, Ramon
    JOURNAL OF THORACIC DISEASE, 2017, 9 (01) : 13 - 15
  • [24] SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013
    Camps, C.
    Felip, E.
    Garcia-Campelo, R.
    Trigo, J. M.
    Garrido, P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (12) : 977 - 984
  • [25] Management of stage III non-small cell lung cancer
    Tabchi, Samer
    Kassouf, Elie
    El Rassy, Elie
    Kourie, Hampig Raphael
    Martin, Jocelyne
    Campeau, Marie-Pierre
    Tehfe, Mustapha
    Blais, Normand
    SEMINARS IN ONCOLOGY, 2017, 44 (03) : 163 - 177
  • [26] Clinical factors and prognosis in non-small cell lung cancer
    Martins, SJ
    Pereira, JR
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (05): : 453 - 457
  • [27] Emerging treatment options in the management of non-small cell lung cancer
    Filosso, Pier Luigi
    Sandri, Alberto
    Oliaro, Alberto
    Filippi, Andrea Riccardo
    Cassinis, Maria Carla
    Ricardi, Umberto
    Lausi, Paolo Olivo
    Asioli, Sofia
    Ruffini, Enrico
    LUNG CANCER-TARGETS AND THERAPY, 2011, 2 : 11 - 28
  • [28] Patients' confidence in treatment decisions for early stage non-small cell lung cancer (NSCLC)
    Pompili, Cecilia
    Holch, Patricia
    Rogers, Zoe
    Absolom, Kate
    Clayton, Beverly
    Franks, Kevin
    Bekker, Hilary
    Velikova, Galina
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2020, 18 (01)
  • [29] Variations in Receipt of Curative-Intent Surgery for Early-Stage Non-Small Cell Lung Cancer (NSCLC) by State
    Sineshaw, Helmneh M.
    Wu, Xiao-Cheng
    Flanders, W. Dana
    Osarogiagbon, Raymond Uyiosa
    Jemal, Ahmedin
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) : 880 - 889
  • [30] International Patterns of Radiotherapy Practice for Non-Small Cell Lung Cancer
    Vinod, Shalini K.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S448 - S448